Given that up to 20% of new cases of colorectal cancer present with metastatic disease, and of the patients who present with localized disease, about 20% will subsequently relapse with distant metastases [4], targeting tenascin-C would constitute a promising strategy in our effort to combat micrometastasis. Here, TNC is linked to colorectal cancer.